Download
41375_2024_Article_2401.pdf 2,14MB
WeightNameValue
1000 Titel
  • Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
1000 Autor/in
  1. Willis, Brandon S. |
  2. Mongeon, Kevin |
  3. Dry, Hannah |
  4. Neveras, India L. |
  5. Bryan, Nadezda |
  6. Pandya, Meghana |
  7. Roderick-Richardson, Justine |
  8. Xu, Wendan |
  9. Yang, Li |
  10. Rosen, Alan |
  11. Reimer, Corinne |
  12. Tuskova, Liliana |
  13. Klener, Pavel |
  14. Mettetal, Jerome T. |
  15. Lenz, Georg |
  16. Barry, Simon |
1000 Verlag Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-09-16
1000 Erschienen in
1000 Quellenangabe
  • 38(12):2663-2674
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-024-02401-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588655/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-α/δ inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL <jats:italic>PTEN</jats:italic> wildtype cell lines and those harbouring <jats:italic>PTEN</jats:italic> mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL.</jats:p>
1000 Sacherschließung
lokal Proto-Oncogene Proteins c-bcl-2/antagonists
lokal Rituximab/pharmacology [MeSH]
lokal Cell Line, Tumor [MeSH]
lokal Bridged Bicyclo Compounds, Heterocyclic/pharmacology [MeSH]
lokal Sulfonamides/therapeutic use [MeSH]
lokal Rituximab/therapeutic use [MeSH]
lokal Bridged Bicyclo Compounds, Heterocyclic/therapeutic use [MeSH]
lokal Xenograft Model Antitumor Assays [MeSH]
lokal Pyrroles/pharmacology [MeSH]
lokal Pyrimidines/pharmacology [MeSH]
lokal Lymphoma, Large B-Cell, Diffuse/drug therapy [MeSH]
lokal Humans [MeSH]
lokal Pyrroles/therapeutic use [MeSH]
lokal Apoptosis/drug effects [MeSH]
lokal Sulfonamides/pharmacology [MeSH]
lokal /692/308/2778
lokal Animals [MeSH]
lokal /64/60
lokal Mice, SCID [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Lymphoma, Large B-Cell, Diffuse/pathology [MeSH]
lokal PTEN Phosphohydrolase/metabolism [MeSH]
lokal /692/699/1541/1990
lokal Mice [MeSH]
lokal Article
lokal Pyrimidines/therapeutic use [MeSH]
lokal Proto-Oncogene Proteins c-bcl-2/metabolism [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/pharmacology [MeSH]
lokal Proto-Oncogene Proteins c-akt/metabolism [MeSH]
lokal /13/95
lokal Cell Proliferation/drug effects [MeSH]
lokal article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/V2lsbGlzLCBCcmFuZG9uIFMu|https://frl.publisso.de/adhoc/uri/TW9uZ2VvbiwgS2V2aW4=|https://frl.publisso.de/adhoc/uri/RHJ5LCBIYW5uYWg=|https://frl.publisso.de/adhoc/uri/TmV2ZXJhcywgSW5kaWEgTC4=|https://frl.publisso.de/adhoc/uri/QnJ5YW4sIE5hZGV6ZGE=|https://frl.publisso.de/adhoc/uri/UGFuZHlhLCBNZWdoYW5h|https://frl.publisso.de/adhoc/uri/Um9kZXJpY2stUmljaGFyZHNvbiwgSnVzdGluZQ==|https://frl.publisso.de/adhoc/uri/WHUsIFdlbmRhbg==|https://frl.publisso.de/adhoc/uri/WWFuZywgTGk=|https://frl.publisso.de/adhoc/uri/Um9zZW4sIEFsYW4=|https://frl.publisso.de/adhoc/uri/UmVpbWVyLCBDb3Jpbm5l|https://frl.publisso.de/adhoc/uri/VHVza292YSwgTGlsaWFuYQ==|https://frl.publisso.de/adhoc/uri/S2xlbmVyLCBQYXZlbA==|https://frl.publisso.de/adhoc/uri/TWV0dGV0YWwsIEplcm9tZSBULg==|https://orcid.org/0000-0002-4728-1693|https://orcid.org/0000-0002-8511-0588
1000 Hinweis
  • DeepGreen-ID: 74d0c2fc0a2d4deeaaf282201d837a80 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. AstraZeneca providing funding to support experiments |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer AstraZeneca providing funding to support experiments |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6495292.rdf
1000 Erstellt am 2025-02-04T08:10:26.327+0100
1000 Erstellt von 322
1000 beschreibt frl:6495292
1000 Zuletzt bearbeitet 2025-09-14T01:34:31.414+0200
1000 Objekt bearb. Sun Sep 14 01:34:31 CEST 2025
1000 Vgl. frl:6495292
1000 Oai Id
  1. oai:frl.publisso.de:frl:6495292 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source